Channing J Der

List of Publications by Year in Descending Order

310 papers	36,455 citations	94 h-index	186 g-index
408 ext. papers	40,113 ext. citations	9.6 avg, IF	7.29 L-index

#	Paper	IF	Citations
310	Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.. *Advances in Cancer Research*, **2022**, 153, 101-130	5.9	0
309	Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).. *Journal of Clinical Oncology*, **2022**, 40, TPS634-TPS634	2.2	
308	KRAS-Independent Macropinocytosis in Pancreatic Cancer.. *Sub-Cellular Biochemistry*, **2022**, 98, 205-221	5.5	1
307	Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.. *Molecular Cancer Therapeutics*, **2022**,	6.1	1
306	CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. *Cell Reports*, **2021**, 37, 110060	10.6	3
305	Filling in the GAPs in understanding RAS. *Science*, **2021**, 374, 152-153	33.3	
304	The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer. *Journal of Biological Chemistry*, **2021**, 297, 101335	5.4	2
303	Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. *Cell Reports*, **2021**, 35, 109291	10.6	2
302	Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice. *Gut*, **2021**, 70, 654-665	19.2	17
301	Validation of Isoform- and Mutation-Specific RAS Antibodies. *Methods in Molecular Biology*, **2021**, 2262, 91-103	1.4	1
300	G-proteins | Small GTPases **2021**, 488-495		
299	Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. *ACS Pharmacology and Translational Science*, **2021**, 4, 703-712	5.9	3
298	The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. *Biochemical Society Transactions*, **2021**, 49, 253-267	5.1	11
297	New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. *Gastroenterology*, **2021**, 161, 785-791	13.3	1
296	KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. *Cancer Letters*, **2021**, 517, 66-77	9.9	3
295	Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors.. *Cancer Research*, **2021**,	10.1	6
294	Analysis of RAS protein interactions in living cells reveals a mechanism for pan-RAS depletion by membrane-targeted RAS binders. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 12121-12130	11.5	8

293	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. *Cancer Cell*, **2020**, 38, 198-211.e8	24.3	38
292	Binge Drinking: Macropinocytosis Promotes Tumorigenic Growth of RAS-Mutant Cancers. *Trends in Biochemical Sciences*, **2020**, 45, 459-461	10.3	6
291	RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. *Science Signaling*, **2020**, 13,	8.8	36
290	Genome-wide DNA methylation analysis of KRAS mutant cell lines. *Scientific Reports*, **2020**, 10, 10149	4.9	2
289	Atypical KRAS Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. *Cancer Discovery*, **2020**, 10, 104-123	24.4	70
288	Gain-of-Function Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. *Cancer Discovery*, **2020**, 10, 288-305	24.4	41
287	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. *Cell Reports*, **2020**, 31, 107764	10.6	31
286	RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?. *Critical Reviews in Biochemistry and Molecular Biology*, **2020**, 55, 386-407	8.7	7
285	Ultrastructure of Human Pancreatic Cancer Cells Treated with a TBK1 Inhibitor. *Microscopy and Microanalysis*, **2019**, 25, 1284-1285	0.5	1
284	RAS Mutations Are Not Created Equal. *Cancer Discovery*, **2019**, 9, 696-698	24.4	11
283	Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. *Nature Medicine*, **2019**, 25, 628-640	50.5	281
282	Blocking autophagy to starve pancreatic cancer. *Nature Reviews Molecular Cell Biology*, **2019**, 20, 265	48.7	14
281	Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. *Science Signaling*, **2019**, 12,	8.8	25
280	Filling GAPs in our knowledge: ARHGAP11A and RACGAP1 act as oncogenes in basal-like breast cancers. *Small GTPases*, **2018**, 9, 290-296	2.7	21
279	KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	296
278	KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. *Cancer Cell*, **2018**, 34, 807-822.e7	24.3	71
277	Computational design of chemogenetic and optogenetic split proteins. *Nature Communications*, **2018**, 9, 4042	17.4	49
276	RHOA mutations in cancer: Oncogenes or tumor suppressors? **2018**, 121-138		

275	Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma. *Cancer Cell*, **2017**, 31, 256-269	24.3	69
274	Mutant RAS Calms Stressed-Out Cancer Cells. *Developmental Cell*, **2017**, 40, 120-122	10.2	3
273	A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation. *Journal of Biological Chemistry*, **2017**, 292, 4446-4456	5.4	20
272	Drugging RAS: Know the enemy. *Science*, **2017**, 355, 1158-1163	33.3	207
271	Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. *Science Signaling*, **2017**, 10,	8.8	37
270	A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. *Cell Reports*, **2017**, 20, 999-1015	10.6	45
269	Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability. *PLoS ONE*, **2017**, 12, e0174863	3.7	10
268	The role of wild type RAS isoforms in cancer. *Seminars in Cell and Developmental Biology*, **2016**, 58, 60-9	7.5	70
267	ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma. *Molecular Cancer Research*, **2016**, 14, 1009-1018	6.6	16
266	Protein Kinase CK2 Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2 Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. *Journal of Biological Chemistry*, **2016**, 291, 17804-15	5.4	21
265	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
264	Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It's Down. *Cancer Cell*, **2016**, 29, 251-253	25.3	39
263	RAS isoforms and mutations in cancer at a glance. *Journal of Cell Science*, **2016**, 129, 1287-92	5.3	397
262	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. *Cancer Cell*, **2016**, 29, 75-89	24.3	145
261	Characterization of an Engineered Src Kinase to Study Src Signaling and Biology. *Methods in Molecular Biology*, **2016**, 1360, 157-67	1.4	4
260	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. *Cancers*, **2016**, 8,	6.6	106
259	Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. *Cancer Research*, **2016**, 76, 3826-37	10.1	40
258	Seeing is believing: Ras dimers observed in live cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 9793-4	11.5	12

257	CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2015**, 152, 337-46	4.4	19
256	Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?. *Clinical Cancer Research*, **2015**, 21, 1819-27	12.9	236
255	Targeting -mutant cancers: is ERK the key?. *Trends in Cancer*, **2015**, 1, 183-198	12.5	78
254	Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases. *Journal of Biological Chemistry*, **2015**, 290, 22851-61	5.4	28
253	Substrate trapping proteomics reveals targets of the rCP2/FBXW11 ubiquitin ligase. *Molecular and Cellular Biology*, **2015**, 35, 167-81	4.8	37
252	The C. elegans Chp/Wrch Ortholog CHW-1 Contributes to LIN-18/Ryk and LIN-17/Frizzled Signaling in Cell Polarity. *PLoS ONE*, **2015**, 10, e0133226	3.7	6
251	Drugging the undruggable RAS: Mission possible?. *Nature Reviews Drug Discovery*, **2014**, 13, 828-51	64.1	1081
250	Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2014**, 1843, 2976-2988	4.9	71
249	Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. *Clinical Cancer Research*, **2014**, 20, 4740-6	12.9	35
248	Ral and Rheb GTPase activating proteins integrate mTOR and GTPase signaling in aging, autophagy, and tumor cell invasion. *Molecular Cell*, **2014**, 53, 209-20	17.6	89
247	KRAS: feeding pancreatic cancer proliferation. *Trends in Biochemical Sciences*, **2014**, 39, 91-100	10.3	422
246	P-Rex1 directly activates RhoG to regulate GPCR-driven Rac signalling and actin polarity in neutrophils. *Journal of Cell Science*, **2014**, 127, 2589-600	5.3	42
245	Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. *Molecular Cancer Therapeutics*, **2014**, 13, 122-33	6.1	15
244	RAS Genes and Cancer **2014**, 157-171		
243	Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers **2014**, 135-156		3
242	Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. *Cancer Discovery*, **2013**, 3, 294-307	24.4	50
241	Mechanisms of targeted therapy resistance take a de-TOR. *Cancer Cell*, **2013**, 24, 284-6	24.3	5
240	Mutant and wild-type Ras: co-conspirators in cancer. *Cancer Discovery*, **2013**, 3, 24-6	24.4	13

239	The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. *Genes and Cancer*, **2013**, 4, 460-75	2.9	40
238	Inhibitors of the ROCK serine/threonine kinases: key effectors of the RhoA small GTPase. *The Enzymes*, **2013**, 33 Pt A, 193-212	2.3	5
237	Redundant canonical and noncanonical Caenorhabditis elegans p21-activated kinase signaling governs distal tip cell migrations. *G3: Genes, Genomes, Genetics*, **2013**, 3, 181-95	3.2	11
236	TEM4 is a junctional Rho GEF required for cell-cell adhesion, monolayer integrity and barrier function. *Journal of Cell Science*, **2013**, 126, 3271-7	5.3	29
235	CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 16868-73	11.5	45
234	Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. *Journal of Biological Chemistry*, **2013**, 288, 33156-70	5.4	66
233	Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers. *The Enzymes*, **2013**, 34 Pt. B, 67-106	2.3	6
232	The RhoGEF TEM4 Regulates Endothelial Cell Migration by Suppressing Actomyosin Contractility. *PLoS ONE*, **2013**, 8, e66260	3.7	12
231	Mutational Activation of KRAS and BRAF in Colorectal Cancer **2013**, 121-156		1
230	The RAF inhibitor paradox revisited. *Cancer Cell*, **2012**, 21, 147-9	24.3	16
229	Differential involvement of RalA and RalB in colorectal cancer. *Small GTPases*, **2012**, 3, 126-30	2.7	23
228	Phosphorylation by protein kinase C regulates RalB small GTPase protein activation, subcellular localization, and effector utilization. *Journal of Biological Chemistry*, **2012**, 287, 14827-36	5.4	28
227	The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. *Molecular and Cellular Biology*, **2012**, 32, 1374-86	4.8	50
226	ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. *Cancer Research*, **2012**, 72, 5338-47	10.1	98
225	Identification of a novel actin-binding domain within the Rho guanine nucleotide exchange factor TEM4. *PLoS ONE*, **2012**, 7, e41876	3.7	19
224	Posttranslational lipid modification of Rho family small GTPases. *Methods in Molecular Biology*, **2012**, 827, 87-95	1.4	15
223	Inhibition of Ras for cancer treatment: the search continues. *Future Medicinal Chemistry*, **2011**, 3, 1787-808	4.1	296
222	RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. *Small GTPases*, **2011**, 2, 202-210	2.7	28

221	Ras effector switching promotes divergent cell fates in C. elegans vulval patterning. *Developmental Cell*, **2011**, 20, 84-96	10.2	45
220	Are all KRAS mutations created equal?. *Lancet Oncology, The*, **2011**, 12, 717-8	21.7	11
219	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. *Nature Communications*, **2011**, 2, 555	17.4	132
218	Lipid Modification of Ras Superfamily GTPases. *The Enzymes*, **2011**, 59-95	2.3	6
217	The ect2 rho Guanine nucleotide exchange factor is essential for early mouse development and normal cell cytokinesis and migration. *Genes and Cancer*, **2011**, 2, 932-42	2.9	27
216	Activation and involvement of Ral GTPases in colorectal cancer. *Cancer Research*, **2011**, 71, 206-15	10.1	64
215	The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. *Genes and Cancer*, **2011**, 2, 275-87	2.9	83
214	Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation. *Journal of Biological Chemistry*, **2011**, 286, 8149-8157	5.4	64
213	Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. *Nature Reviews Cancer*, **2010**, 10, 842-57	31.3	529
212	The Roles of Ras Family Small GTPases in Breast Cancer **2010**, 2763-2772		1
211	Role of R-Ras in Cell Growth **2010**, 1753-1762		1
210	Targeting Ras for Anticancer Drug Discovery **2010**, 2837-2857		
209	Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms. *Journal of Biological Chemistry*, **2010**, 285, 34729-40	5.4	45
208	Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. *Molecular and Cellular Biology*, **2010**, 30, 508-23	4.8	91
207	A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. *PLoS Medicine*, **2010**, 7, e1000307	11.6	163
206	Overview of Rho GTPase History **2010**, 3-27		1
205	Ras history: The saga continues. *Small GTPases*, **2010**, 1, 2-27	2.7	457
204	Nitric oxide-releasing silica nanoparticle inhibition of ovarian cancer cell growth. *Molecular Pharmaceutics*, **2010**, 7, 775-85	5.6	81

203	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. *Journal of Clinical Oncology*, **2010**, 28, 4769-77	2.2	214
202	The raf inhibitor paradox: unexpected consequences of targeted drugs. *Cancer Cell*, **2010**, 17, 221-3	24.3	29
201	Ras-related small GTPases RalA and RalB regulate cellular survival after ionizing radiation. *International Journal of Radiation Oncology Biology Physics*, **2010**, 78, 205-12	4	19
200	Transformation by a nucleotide-activated P2Y receptor is mediated by activation of Galphai, Galphaq and Rho-dependent signaling pathways. *Journal of Molecular Signaling*, **2010**, 5, 11	1	8
199	TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. *Journal of Molecular Signaling*, **2010**, 5, 18	1	17
198	Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. *Journal of Molecular Signaling*, **2010**, 5, 2	1	32
197	Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. *Journal of Biological Chemistry*, **2009**, 284, 6227-40	5.4	47
196	K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. *Molecular Cancer Research*, **2009**, 7, 799-808	6.6	61
195	Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition. *Journal of Molecular Signaling*, **2009**, 4, 5	1	5
194	KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. *Molecular Cancer Therapeutics*, **2009**, 8, 834-43	6.1	127
193	Regulation of Rnd3 localization and function by protein kinase C alpha-mediated phosphorylation. *Biochemical Journal*, **2009**, 424, 153-61	3.8	49
192	Regulator of G-protein signaling 14 (RGS14) is a selective H-Ras effector. *PLoS ONE*, **2009**, 4, e4884	3.7	35
191	Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. *Methods in Enzymology*, **2008**, 439, 111-29	1.7	72
190	Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. *Molecular Cancer Research*, **2008**, 6, 435-45	6.6	44
189	Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. *Journal of Biological Chemistry*, **2008**, 283, 32762-70	5.4	46
188	Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. *Journal of Biological Chemistry*, **2008**, 283, 25150-25163	5.4	228
187	Tools to study the function of the Ras-related, estrogen-regulated growth inhibitor in breast cancer. *Methods in Enzymology*, **2008**, 439, 53-72	1.7	6
186	Use of Caenorhabditis elegans to evaluate inhibitors of Ras function in vivo. *Methods in Enzymology*, **2008**, 439, 425-49	1.7	15

185	Ras-driven transformation of human nestin-positive pancreatic epithelial cells. *Methods in Enzymology*, **2008**, 439, 451-65	1.7	16
184	DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. *Molecular Carcinogenesis*, **2008**, 47, 326-37	5	103
183	Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling. *Molecular Carcinogenesis*, **2007**, 46, 958-70	5	13
182	Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. *Nature Structural and Molecular Biology*, **2007**, 14, 814-23	17.6	73
181	Targeting signal transduction in pancreatic cancer treatment. *Expert Opinion on Therapeutic Targets* , **2007**, 11, 673-94	6.4	43
180	Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. *Molecular and Cellular Biology* , **2007**, 27, 8003-14	4.8	66
179	K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. *Cancer Research*, **2007**, 67, 2098-106	10.1	173
178	Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. *Cancer Research*, **2007**, 67, 1502-12	10.1	75
177	Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. *Molecular Cancer Therapeutics*, **2007**, 6, 2220-9	6.1	30
176	Auto-inhibition of the Dbl family protein Tim by an N-terminal helical motif. *Journal of Biological Chemistry*, **2007**, 282, 13813-23	5.4	37
175	Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. *Journal of Biological Chemistry*, **2007**, 282, 35666-78	5.4	231
174	Stopping ras in its tracks. *Cell*, **2007**, 129, 855-7	56.2	17
173	Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. *Current Biology*, **2006**, 16, 2385-94	6.3	186
172	RhoE is a pro-survival p53 target gene that inhibits ROCK I-mediated apoptosis in response to genotoxic stress. *Current Biology*, **2006**, 16, 2466-72	6.3	88
171	Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis. *Methods in Enzymology*, **2006**, 407, 195-217	1.7	19
170	Characterization of RERG: an estrogen-regulated tumor suppressor gene. *Methods in Enzymology*, **2006**, 407, 513-27	1.7	15
169	Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. *Methods in Enzymology*, **2006**, 407, 556-74	1.7	20
168	The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 8173-8	11.5	133

167	Multiple sequence elements facilitate Chp Rho GTPase subcellular location, membrane association, and transforming activity. *Molecular Biology of the Cell*, **2006**, 17, 3108-21	3.5	29
166	Real-time in vitro measurement of intrinsic and Ras GAP-mediated GTP hydrolysis. *Methods in Enzymology*, **2006**, 407, 9-22	1.7	18
165	Biochemical analyses of the Wrch atypical Rho family GTPases. *Methods in Enzymology*, **2006**, 406, 11-26	1.7	19
164	Cellular Assays of Oncogene Transformation **2006**, 345-352		2
163	Citron kinase, a RhoA effector, enhances HIV-1 virion production by modulating exocytosis. *Traffic*, **2006**, 7, 1643-53	5.7	44
162	Ras Stories: The State of the Art **2006**, 1-14		
161	Effectors of Ras-Mediated Oncogenesis **2006**, 121-142		
160	Anti-Ras Strategies for Cancer Treatment **2006**, 353-380		
159	RHO Proteins in RAS Signaling and Transformation **2006**, 143-167		
158	Real-time in vitro measurement of GTP hydrolysis. *Methods*, **2005**, 37, 183-89	4.6	22
157	The Ras superfamily at a glance. *Journal of Cell Science*, **2005**, 118, 843-6	5.3	991
156	GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. *Nature Reviews Molecular Cell Biology*, **2005**, 6, 167-80	48.7	1316
155	Activation of RalA is critical for Ras-induced tumorigenesis of human cells. *Cancer Cell*, **2005**, 7, 533-45	24.3	291
154	Signaling interplay in Ras superfamily function. *Current Biology*, **2005**, 15, R563-74	6.3	284
153	Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. *Journal of Biological Chemistry*, **2005**, 280, 23363-70	5.4	85
152	Transforming activity of the Rho family GTPase, Wrch-1, a Wnt-regulated Cdc42 homolog, is dependent on a novel carboxyl-terminal palmitoylation motif. *Journal of Biological Chemistry*, **2005**, 280, 33055-65	5.4	63
151	Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 12879-84	11.5	285
150	Critical and distinct roles of amino- and carboxyl-terminal sequences in regulation of the biological activity of the Chp atypical Rho GTPase. *Journal of Biological Chemistry*, **2005**, 280, 13784-92	5.4	53

149	Ras Signaling, Deregulation of Gene Expression and Oncogenesis **2004**, 189-208		22
148	Identification and characterization of rain, a novel Ras-interacting protein with a unique subcellular localization. *Journal of Biological Chemistry*, **2004**, 279, 22353-61	5.4	57
147	Requirement for C-terminal sequences in regulation of Ect2 guanine nucleotide exchange specificity and transformation. *Journal of Biological Chemistry*, **2004**, 279, 25226-33	5.4	44
146	p68RacGAP is a novel GTPase-activating protein that interacts with vascular endothelial zinc finger-1 and modulates endothelial cell capillary formation. *Journal of Biological Chemistry*, **2004**, 279, 17963-72	5.4	23
145	SGEF, a RhoG guanine nucleotide exchange factor that stimulates macropinocytosis. *Molecular Biology of the Cell*, **2004**, 15, 3309-19	3.5	89
144	Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. *Cancer Research*, **2004**, 64, 4585-92	10.1	171
143	Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. *Molecular and Cellular Biology*, **2004**, 24, 1990-9	4.8	94
142	Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. *Journal of Biological Chemistry*, **2004**, 279, 33168-76	5.4	118
141	Rho-family GTPases: it's not only Rac and Rho (and I like it). *Journal of Cell Science*, **2004**, 117, 1301-12	5.3	469
140	Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. *Oncogene*, **2004**, 23, 9369-80	9.2	146
139	Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. *Trends in Cell Biology*, **2004**, 14, 639-47	18.3	258
138	Oncogenic Ras and its role in tumor cell invasion and metastasis. *Seminars in Cancer Biology*, **2004**, 14, 105-14	12.7	219
137	Atypical mechanism of regulation of the Wrch-1 Rho family small GTPase. *Current Biology*, **2004**, 14, 2052-6	6.9	66
136	Molecular basis for Rho GTPase signaling specificity. *Breast Cancer Research and Treatment*, **2004**, 84, 61-71	4.4	79
135	Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. *International Journal of Cancer*, **2004**, 112, 190-9	7.5	40
134	Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. *Journal of Virology*, **2004**, 78, 12987-95	6.6	54
133	Ligand-dependent dynamics and intramolecular signaling in a PDZ domain. *Journal of Molecular Biology*, **2004**, 335, 1105-15	6.5	193
132	Vav Transformation Requires Activation of Multiple GTPases and Regulation of Gene Expression. *Molecular Cancer Research*, **2004**, 2, 702-711	6.6	19

131	ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. *Journal of Cell Biology*, **2003**, 163, 583-95	7.3	424
130	Critical role of the pleckstrin homology domain in Dbs signaling and growth regulation. *Journal of Biological Chemistry*, **2003**, 278, 21188-96	5.4	24
129	Selective deficiency in protein kinase C isoenzyme expression and inadequacy in mitogen-activated protein kinase activation in cord blood T cells. *Biochemical Journal*, **2003**, 370, 497-503	3.8	14
128	Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. *Current Biology*, **2003**, 13, 1106-15	8.3	198
127	Role of the pleckstrin homology domain in intersectin-L Dbl homology domain activation of Cdc42 and signaling. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2003**, 1640, 61-8	4.9	16
126	The dark side of Ras: regulation of apoptosis. *Oncogene*, **2003**, 22, 8999-9006	9.2	354
125	Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. *Nature Reviews Cancer*, **2003**, 3, 945-51	31.3	146
124	Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. *Journal of Biological Chemistry*, **2003**, 278, 35501-7	5.4	288
123	Role of R-Ras in Cell Growth **2003**, 681-688		
122	Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. *Molecular Cancer Research*, **2003**, 1, 1077-88	6.6	10
121	Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. *Nature Cell Biology*, **2002**, 4, 621-5	23.4	258
120	Structural basis for the selective activation of Rho GTPases by Dbl exchange factors. *Nature Structural Biology*, **2002**, 9, 468-75		172
119	Ras family signaling: therapeutic targeting. *Cancer Biology and Therapy*, **2002**, 1, 599-606	4.6	167
118	Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. *Journal of Biological Chemistry*, **2002**, 277, 9790-9	5.4	108
117	RhoG signals in parallel with Rac1 and Cdc42. *Journal of Biological Chemistry*, **2002**, 277, 47810-7	5.4	89
116	Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity. *Journal of Biological Chemistry*, **2002**, 277, 39350-9	5.4	24
115	Involvement of phosphatidylinositol 3-kinase, but not RalGDS, in TC21/R-Ras2-mediated transformation. *Journal of Biological Chemistry*, **2002**, 277, 9966-75	5.4	42
114	Role of MLK3-mediated activation of p70 S6 kinase in Rac1 transformation. *Journal of Biological Chemistry*, **2002**, 277, 4770-7	5.4	18

113	Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. *Molecular and Cellular Biology*, **2002**, 22, 1589-606	4.8	58
112	RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. *Journal of Biological Chemistry*, **2002**, 277, 30508-14	5.4	77
111	Critical but distinct roles for the pleckstrin homology and cysteine-rich domains as positive modulators of Vav2 signaling and transformation. *Molecular and Cellular Biology*, **2002**, 22, 2487-97	4.8	45
110	Distinct requirements for Ras oncogenesis in human versus mouse cells. *Genes and Development*, **2002**, 16, 2045-57	12.6	340
109	Opposing roles of the extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in Ras-mediated downregulation of tropomyosin. *Molecular and Cellular Biology*, **2002**, 22, 2304-17	4.8	62
108	XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. *Journal of Biological Chemistry*, **2002**, 277, 42964-72	5.4	99
107	Leukemia-associated Rho guanine nucleotide exchange factor promotes G alpha q-coupled activation of RhoA. *Molecular and Cellular Biology*, **2002**, 22, 4053-61	4.8	154
106	Role of MAP kinases in the 1,25-dihydroxyvitamin D3-induced transactivation of the rat cytochrome P450C24 (CYP24) promoter. Specific functions for ERK1/ERK2 and ERK5. *Journal of Biological Chemistry*, **2002**, 277, 29643-53	5.4	86
105	Raf-independent deregulation of p38 and JNK mitogen-activated protein kinases are critical for Ras transformation. *Journal of Biological Chemistry*, **2002**, 277, 31808-17	5.4	66
104	Farnesyltransferase inhibitors: promises and realities. *Current Opinion in Pharmacology*, **2002**, 2, 388-93	5.1	108
103	Ras Proteins **2002**, 41-48		
102	RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. *Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research*, **2002**, 13, 363-73		23
101	Analyses of TC21/R-Ras2 signaling and biological activity. *Methods in Enzymology*, **2001**, 333, 203-16	1.7	4
100	Identification of Ras-regulated genes by representational difference analysis. *Methods in Enzymology*, **2001**, 332, 221-32	1.7	4
99	Molecular basis for Rac1 recognition by guanine nucleotide exchange factors. *Nature Structural Biology*, **2001**, 8, 1037-41		78
98	Rho GTPase-dependent transformation by G protein-coupled receptors. *Oncogene*, **2001**, 20, 1547-55	9.2	76
97	The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. *Oncogene*, **2001**, 20, 1953-63	9.2	103
96	Quantitative analysis of the effect of phosphoinositide interactions on the function of Dbl family proteins. *Journal of Biological Chemistry*, **2001**, 276, 45868-75	5.4	78

95	Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase. *Molecular and Cellular Biology*, **2001**, 21, 5488-99	4.8	103
94	The insert region of Rac1 is essential for membrane ruffling but not cellular transformation. *Molecular and Cellular Biology*, **2001**, 21, 2847-57	4.8	34
93	RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. *Journal of Biological Chemistry*, **2001**, 276, 42259-67	5.4	120
92	Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. *Journal of Biological Chemistry*, **2001**, 276, 27145-51	5.4	100
91	Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. *Methods in Enzymology*, **2001**, 332, 3-36	1.7	41
90	Ras and Rho regulation of the cell cycle and oncogenesis. *Cancer Letters*, **2001**, 171, 1-10	9.9	252
89	The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. *Developmental Cell*, **2001**, 1, 63-72	10.2	288
88	Activation of phospholipase C-epsilon by heterotrimeric G protein betagamma-subunits. *Journal of Biological Chemistry*, **2001**, 276, 48257-61	5.4	79
87	Rho Family GTPases Regulate Mammary Epithelium Cell Growth and Metastasis Through Distinguishable Pathways. *Molecular Medicine*, **2001**, 7, 816-830	6.2	83
86	G2A is an oncogenic G protein-coupled receptor. *Oncogene*, **2000**, 19, 3866-77	9.2	62
85	The Ras branch of small GTPases: Ras family members don't fall far from the tree. *Current Opinion in Cell Biology*, **2000**, 12, 157-65	9	350
84	Understanding Ras: it ain't over 'til it's over. *Trends in Cell Biology*, **2000**, 10, 147-54	18.3	682
83	Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells. *Journal of Biological Chemistry*, **2000**, 275, 40916-24	5.4	23
82	Modulation of HIV-1 replication by a novel RhoA effector activity. *Journal of Immunology*, **2000**, 164, 5369-74	5.3	33
81	Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. *Journal of Biological Chemistry*, **2000**, 275, 22172-9	5.4	78
80	Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. *Molecular and Cellular Biology*, **2000**, 20, 8655-66	4.8	83
79	Dissection of Ras-dependent signaling pathways controlling aggressive tumor growth of human fibrosarcoma cells: evidence for a potential novel pathway. *Molecular and Cellular Biology*, **2000**, 20, 9294-306	4.8	45
78	Vav2 is an activator of Cdc42, Rac1, and RhoA. *Journal of Biological Chemistry*, **2000**, 275, 10141-9	5.4	208

77	Analyses of transforming activity of Rho family activators. *Methods in Enzymology*, **2000**, 325, 425-41	1.7	12
76	Analysis of function and regulation of proteins that mediate signal transduction by use of lipid-modified plasma membrane-targeting sequences. *Methods in Enzymology*, **2000**, 327, 331-50	1.7	18
75	Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. *Journal of Biological Chemistry*, **1999**, 274, 27545-52	5.4	221
74	M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6. *Journal of Biological Chemistry*, **1999**, 274, 23850-7	5.4	97
73	Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway. *Journal of Biological Chemistry*, **1999**, 274, 25245-9	5.4	236
72	Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity. *Journal of Biological Chemistry*, **1999**, 274, 30410-8	5.4	45
71	Splice variants of intersectin are components of the endocytic machinery in neurons and nonneuronal cells. *Journal of Biological Chemistry*, **1999**, 274, 15671-7	5.4	151
70	A non-farnesylated Ha-Ras protein can be palmitoylated and trigger potent differentiation and transformation. *Journal of Biological Chemistry*, **1999**, 274, 1423-31	5.4	51
69	Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. *Oncogene*, **1999**, 18, 1807-17	9.2	47
68	TC21 and Ras share indistinguishable transforming and differentiating activities. *Oncogene*, **1999**, 18, 2107-16	9.2	54
67	Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth. *Oncogene*, **1999**, 18, 3831-45	9.2	82
66	GTP binding by class II transactivator: role in nuclear import. *Science*, **1999**, 285, 1402-5	33.3	87
65	Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. *Gastroenterology*, **1999**, 117, 567-76	13.3	34
64	Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation. *Molecular and Cellular Biology*, **1999**, 19, 7759-70	4.8	101
63	Increasing complexity of Ras signal transduction: involvement of Rho family proteins. *Advances in Cancer Research*, **1998**, 72, 57-107	5.9	133
62	Ras, but not Src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade. *Oncogene*, **1998**, 16, 2565-73	9.2	46
61	Increasing complexity of Ras signaling. *Oncogene*, **1998**, 17, 1395-413	9.2	903
60	Rho family proteins and Ras transformation: the RHOad less traveled gets congested. *Oncogene*, **1998**, 17, 1415-38	9.2	316

59	Differential regulation of SHC proteins by nerve growth factor in sensory neurons and PC12 cells. *European Journal of Neuroscience*, **1998**, 10, 1995-2008	3.5	52
58	Increasing complexity of the Ras signaling pathway. *Journal of Biological Chemistry*, **1998**, 273, 19925-8	5.4	438
57	CD45 and Src-related protein tyrosine kinases regulate the T cell response to phorbol esters. *Biochemical and Biophysical Research Communications*, **1998**, 243, 444-50	3.4	4
56	The src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor. *Journal of Biological Chemistry*, **1998**, 273, 20431-7	5.4	24
55	Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun. *Journal of Biological Chemistry*, **1998**, 273, 16739-47	5.4	79
54	Stimulation of p38 phosphorylation and activity by arachidonic acid in HeLa cells, HL60 promyelocytic leukemic cells, and human neutrophils. Evidence for cell type-specific activation of mitogen-activated protein kinases. *Journal of Biological Chemistry*, **1998**, 273, 19277-82	5.4	87
53	Regulation of RasGRP via a phorbol ester-responsive C1 domain. *Molecular and Cellular Biology*, **1998**, 18, 6995-7008	4.8	205
52	CDC42 and FGD1 cause distinct signaling and transforming activities. *Molecular and Cellular Biology*, **1998**, 18, 4689-97	4.8	56
51	Mas oncogene signaling and transformation require the small GTP-binding protein Rac. *Molecular and Cellular Biology*, **1998**, 18, 1225-35	4.8	68
50	The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation. *Journal of Biological Chemistry*, **1997**, 272, 10608-15	5.4	140
49	14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain. *Journal of Biological Chemistry*, **1997**, 272, 20990-3	5.4	103
48	A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. *Journal of Biological Chemistry*, **1997**, 272, 18926-31	5.4	90
47	Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. *Journal of Biological Chemistry*, **1997**, 272, 24113-6	5.4	308
46	p120 GAP modulates Ras activation of Jun kinases and transformation. *Journal of Biological Chemistry*, **1997**, 272, 1677-81	5.4	84
45	Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. *Science*, **1997**, 278, 1812-5	33.3	494
44	R-Ras is regulated by activators and effectors distinct from those that control Ras function. *Oncogene*, **1997**, 14, 133-43	9.2	47
43	Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. *Nature*, **1997**, 390, 632-6	50.4	640
42	Dbl family proteins. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1997**, 1332, F1-23	11.2	112

41	Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1997**, 1333, F51-71	11.2	95
40	The coupling of alpha6beta4 integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation. *EMBO Journal*, **1997**, 16, 2365-75	13	270
39	Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras [corrected]. *Journal of Biological Chemistry*, **1996**, 271, 18122-7	5.4	152
38	Expression cloning of lsc, a novel oncogene with structural similarities to the Dbl family of guanine nucleotide exchange factors. *Journal of Biological Chemistry*, **1996**, 271, 18643-50	5.4	70
37	Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors. *Journal of Biological Chemistry*, **1996**, 271, 11076-82	5.4	43
36	Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. *Journal of Biological Chemistry*, **1996**, 271, 233-7	5.4	126
35	The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. *Journal of Biological Chemistry*, **1996**, 271, 6497-501	5.4	368
34	Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1. *Journal of Biological Chemistry*, **1996**, 271, 29903-8	5.4	57
33	Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC. *Journal of Biological Chemistry*, **1996**, 271, 11787-91	5.4	16
32	Isolation of a NCK-associated kinase, PRK2, an SH3-binding protein and potential effector of Rho protein signaling. *Journal of Biological Chemistry*, **1996**, 271, 28772-6	5.4	124
31	Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. *Journal of Biological Chemistry*, **1996**, 271, 7992-8	5.4	102
30	Rek, a gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl/Tyro3 family. *Journal of Biological Chemistry*, **1996**, 271, 29049-59	5.4	21
29	Aberrant function of the Ras signal transduction pathway in human breast cancer. *Breast Cancer Research and Treatment*, **1995**, 35, 133-44	4.4	176
28	Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. *Journal of Biological Chemistry*, **1995**, 270, 26802-6	5.4	283
27	Two distinct Raf domains mediate interaction with Ras. *Journal of Biological Chemistry*, **1995**, 270, 9809-12	5.4	181
26	Biological assays for Ras transformation. *Methods in Enzymology*, **1995**, 255, 395-412	1.7	168
25	Analysis of Ras protein expression in mammalian cells. *Methods in Enzymology*, **1995**, 255, 195-220	1.7	33
24	Targeting proteins to membranes using signal sequences for lipid modification. *Methods in Enzymology*, **1995**, 250, 435-54	1.7	16

23	Prenylation analysis of bacterially expressed and insect cell-expressed Ras and Ras-related proteins. *Methods in Enzymology*, **1995**, 255, 46-60	1.7	12
22	Guanine nucleotide exchange factors: activators of Ras superfamily proteins. *Molecular Reproduction and Development*, **1995**, 42, 468-76	2.6	65
21	Guanine nucleotide exchange factors: activators of the Ras superfamily of proteins. *BioEssays*, **1995**, 17, 395-404	4.1	185
20	ras Proto-Oncogene Activation in Human Malignancy **1995**, 17-52		19
19	The Ras signal transduction pathway. *Cancer and Metastasis Reviews*, **1994**, 13, 67-89	9.6	315
18	Transcriptional activation analysis of oncogene function. *Methods in Enzymology*, **1994**, 238, 271-6	1.7	13
17	Biological assays for cellular transformation. *Methods in Enzymology*, **1994**, 238, 277-94	1.7	83
16	BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. *Cell*, **1993**, 75, 175-185	56.2	576
15	Emerging concepts in the Ras superfamily of GTP-binding proteins. *FASEB Journal*, **1993**, 7, 750-9	0.9	191
14	Structure and biological effects of lipid modifications on proteins. *Current Opinion in Cell Biology*, **1992**, 4, 629-36	9	32
13	Alterations in transformation efficiency by the ADPRT-inhibitor 3-aminobenzamide are oncogene specific. *Carcinogenesis*, **1989**, 10, 383-5	4.6	11
12	Activation of ras oncogenes in chemically transformed BALB/MK-2 mouse keratinocytes. *Molecular Carcinogenesis*, **1989**, 2, 150-8	5	8
11	Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. *Cell*, **1989**, 59, 33-43	56.2	367
10	Activation of cellular p21ras by myristoylation. *Biochemical Society Transactions*, **1989**, 17, 867-9	5.1	6
9	The ras family of oncogenes. *Cancer Treatment and Research*, **1989**, 47, 73-119	3.5	14
8	Biological and biochemical properties of human rasH genes mutated at codon 61. *Cell*, **1986**, 44, 167-76	56.2	481
7	Activation of ras genes in human tumors does not affect localization, modification, or nucleotide binding properties of p21. *Cell*, **1984**, 37, 151-8	56.2	137
6	Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas. *Cell*, **1983**, 32, 201-8	56.2	152

5	A tumor-specific membrane phosphoprotein marker in human cell hybrids. *Cell*, **1981**, 26, 429-38	56.2	72
4	Alterations in the extracellular matrix organization associated with the reexpression of tumorigenicity in human cell hybrids. *International Journal of Cancer*, **1980**, 26, 451-9	7.5	28
3	Lack of correlation between the decreased expression of cell surface LETS protein and tumorigenicity in human cell hybrids. *Cell*, **1978**, 15, 1241-51	56.2	68
2	Ras-Mediated Deregulation of Gene Expression and Contribution to Oncogenesis77-100		4
1	Ras Oncoproteins1		